Low risk of secondary tumors after CAR-T cell therapy

medicine Tuesday, 18 June 2024 Standford – The risk of secondary cancer after CAR-T cell therapy is low, according to an evaluation by Stanford University. Researchers took a closer look at around 700 patients who